Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CDK Inhibitor
Eciruciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), primarily targeting CDK2, CDK4, and CDK6. It demonstrates significant antineoplastic activity, making it a valuable tool for cancer research. This compound is employed in studies aimed at understanding cell cycle regulation and developing targeted therapies for various malignancies. -
Cdk2/9 Inhibitor
CK7 is a potent inhibitor of cyclin-dependent kinases Cdk2 and Cdk9. It demonstrates significant biological activity in modulating cell cycle progression and transcriptional regulation. This reagent is particularly useful in research applications focused on cancer biology and the development of novel therapeutics targeting the cell cycle. Additionally, CK7 serves as a synthetic precursor for the production of Nek1 inhibitors BSc5231 and BSc5367. -
CDK4/6 Inhibitor
CGP-82996 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates IC50 values of 1.5 μM, 5.6 μM, and 25 μM against CDK4/cyclin D1, CDK6/cyclin D1, and Cdk5/p35, respectively. This compound effectively induces apoptosis in U2OS cancer cells, making it a valuable tool in cancer research to study the modulation of cell cycle progression and cancer cell viability. -
CDK Inhibitor
CDK-IN-6 is a pyrazolo[1,5-a]pyrimidine compound that functions as a cyclin-dependent kinase (CDK) inhibitor. This compound exhibits significant anticancer activity by hindering cell cycle progression, particularly in malignant cells. CDK-IN-6 is utilized in research to explore pathways involved in cancer proliferation and may serve as a valuable tool for investigating therapeutic strategies targeting CDK regulation in various tumors. -
CDK Inhibitor
N9-Isopropylolomoucine is a selective inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CCNB1/CDK1. It plays a critical role in regulating cell cycle progression and mitotic processes. This compound is valuable in cancer research for studying cell proliferation and exploring therapeutic strategies that disrupt tumor growth by targeting CDK activity. -
CDK9/cyclin T1 Inhibitor
CAN508 is a potent ATP-competitive inhibitor of the CDK9/cyclin T1 complex, displaying an IC50 of 0.35 μM. This compound demonstrates a remarkable 38-fold selectivity for CDK9/cyclin T over other cyclin-dependent kinases, making it a valuable tool for investigating transcriptional regulation. Its antitumor activity positions CAN508 as a relevant candidate for research into cancer therapeutics and related signaling pathways. -
CDK4/6 Inhibitor
CDK4/6-IN-12 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates significant enzymatic inhibitory activity, with IC50 values of 592.3 nM for CDK4 and 3090 nM for CDK6. This compound is valuable for cancer research, particularly in studies exploring cell cycle regulation and therapeutic strategies targeting CDK4/6 in tumor cells. -
CDK12 Inhibitor
CDK12-IN-5 is a selective inhibitor of cyclin-dependent kinase 12 (CDK12), exhibiting a potent inhibitory activity with an IC50 of 23.9 nM in the presence of high ATP (2 mM). This compound shows no significant inhibition against CDK2/Cyclin E or CDK9/Cyclin T1, with IC50 values of 173 μM and 127 μM, respectively, under the same conditions. CDK12-IN-5 is valuable for studies investigating the role of CDK12 in transcriptional regulation and its implications in cancer research. -
CDK Inhibitor
CDK5-IN-1 is a selective inhibitor of cyclin-dependent kinase 5 (CDK5), exhibiting an inhibitory concentration (IC50) of less than 10 nM. This compound demonstrates over 100-fold specificity for CDK5 compared to CDK2, making it a valuable tool for studying CDK5-related pathways. CDK5-IN-1 is applicable in research on kidney diseases and offers insights into the molecular mechanisms governing renal function and pathology. -
CDK2 Inhibitor
CDK2-IN-13 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 value of 12 µM. This compound is primarily utilized in cancer research to study the role of CDK2 in cell cycle regulation and tumor proliferation. Its ability to modulate CDK2 activity makes it a valuable tool for investigating potential therapeutic strategies in oncology. -
CDK14/CDK16 Inhibitor
FMF-04-159-R is an inhibitor of cyclin-dependent kinases CDK14 and CDK16, exhibiting IC50 values of 5.9 nM and 139.1 nM, respectively. This compound is primarily utilized in research to explore the roles of CDK14 and CDK16 in cell cycle regulation and transcriptional control. Its selective inhibition may provide insights into therapeutic strategies for diseases linked to dysregulated kinase activity. -
CDK4/6 Inhibitor
CDK4/6-IN-9 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting an IC50 of 905 nM for the CDK6/cyclin D1 complex. This compound demonstrates significant potential in the investigation of multiple myeloma (MM) biology and therapeutic strategies. It is designed to facilitate research focused on cell cycle regulation and the oncogenic pathways associated with MM. -
CDK Inhibitor
(2S,3R)-Voruciclib hydrochloride is a selective inhibitor of cyclin-dependent kinases (CDKs), demonstrating potent activity against various CDK isoforms. This compound is primarily used in the study of cell cycle regulation and cancer biology, providing insights into mechanisms of proliferation and tumor growth. Its oral bioavailability makes it a valuable tool for in vivo research applications in cancer therapeutics. -
CDK Inhibitor
Tanuxiciclib is a selective cyclin-dependent kinase (CDK) inhibitor that targets multiple CDK family members. It exhibits potent antitumor activity through the inhibition of cell cycle progression, making it a valuable tool in cancer research. This compound is utilized in studies investigating cell proliferation, apoptosis, and the mechanisms of cancer cell survival, offering potential insights into novel therapeutic strategies. -
CDK4 Inhibitor
NSC 625987 is a potent CDK4 inhibitor, exhibiting an IC50 of 0.2 μM for the CDK4:cyclin D1 complex. This compound demonstrates more than 500-fold selectivity for CDK4 compared to CDK2, making it a valuable tool for studying cell cycle regulation and cancer biology. Its specificity and efficacy make NSC 625987 suitable for research applications aimed at understanding CDK4's role in tumor proliferation and potential therapeutic strategies. -
CDK7 Inhibitor
SHR5428 is a selective and noncovalent inhibitor of cyclin-dependent kinase 7 (CDK7), exhibiting potent enzymatic activity with an IC50 of 2.3 nM. This compound effectively inhibits cellular activity in triple-negative breast cancer models, specifically in MDA-MB-468 cells, with an IC50 of 6.6 nM. SHR5428 is suitable for research applications involving cell cycle regulation and therapeutic development for aggressive breast cancer forms. -
CDK4 Inhibitor
ZDLD20 is a selective inhibitor of CDK4, exhibiting an IC50 value of 6.51 μM. This β-carboline compound demonstrates significant anti-cancer properties, particularly against HCT116 cells, by inhibiting colony formation, invasion, and migration. Additionally, ZDLD20 promotes apoptosis and induces G1 phase cell cycle arrest, making it a valuable tool for cancer research and therapeutic development. -
CDK2 (Cyclin dependent kinase 2) Inhibitor
CDK2-IN-40 is a potent inhibitor of Cyclin-dependent kinase 2 (CDK2), demonstrating effective inhibition of the CDK2/Cyclin E1 complex with an IC50 value of ≤ 10 nM. This compound plays a significant role in regulating cell cycle progression and is valuable for research applications related to cancer therapy and cellular proliferation studies. CDK2-IN-40 can be utilized to explore the implications of CDK2 inhibition in various biological contexts. -
CDK7 Inhibitor
LDC3140 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of less than 5 nM. By targeting CDK7, LDC3140 disrupts cell cycle regulation, resulting in cell cycle arrest and reduced proliferation of tumor cells. This compound serves as a valuable tool for research focused on cancer therapeutics and the mechanistic understanding of cell cycle dynamics in cancer biology. -
CDK Inhibitor
CDK9-IN-10 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), effectively targeting the transcriptional regulation pathways. This compound serves as a crucial ligand for the PROTAC CDK9 degrader-2, facilitating targeted degradation of CDK9 in cellular studies. Its applications include investigations into oncogenic processes and transcriptional dysregulation, making it a valuable tool for cancer research and drug discovery. -
CDK9 Inhibitor
CDK9-IN-14 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 value of 6.92 nM. This compound demonstrates significant inhibitory activity against MV4;11 cells and exhibits efficacy in in vivo tumor models. Additionally, CDK9-IN-14 shows favorable selectivity and a low toxicity profile, making it suitable for various cancer research applications aimed at targeting transcriptional regulation pathways. -
CDK Inhibitor
Atuveciclib S-Enantiomer is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9). With an IC50 of 16 nM, it effectively inhibits the CDK9/CycT1 complex, playing a crucial role in regulating transcription and cell cycle progression. This compound is primarily utilized in research applications targeting cancer therapeutics and studying transcriptional regulation mechanisms. -
CDK7 Inhibitor
CDK7-IN-1 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound effectively modulates CDK7 activity, disrupting cell cycle progression and transcription regulation. CDK7-IN-1 is suitable for research applications related to cancer biology and therapeutic development targeting aberrant cell proliferation. -
CDK7 Inhibitor
IV-361 is a selective cyclin-dependent kinase 7 (CDK7) inhibitor with a Ki value of less than 50 nM. This compound exhibits significant anti-cancer activity, making it a valuable tool for researchers investigating cancer cell proliferation and survival pathways. IV-361's specificity for CDK7 allows for in-depth studies of its role in transcription regulation and potential therapeutic applications in cancer treatment. -
CDK4 Inhibitor
Cimpuciclib tosylate is a potent selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 0.49 nM. Its strong inhibitory activity is associated with anti-tumor effects and promotes cell cycle arrest in cancer research. This compound is valuable for studies focused on tumor proliferation and therapeutic strategies targeting CDK4 in various cancer types. -
CDK4/6 Inhibitor
CDK4/6-IN-18 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates the ability to effectively inhibit ionizing radiation-induced DNA damage in cellular models. This compound is a valuable tool for research focused on cancer biology and therapies that target the cell cycle and DNA damage response pathways. -
CDK6 Inhibitor
CDK6-IN-1 is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), functioning primarily by impeding cell growth and promoting G1-phase cell cycle arrest. This compound has significant implications in cancer research, particularly in studies targeting cell proliferation and tumorigenesis. Its efficacy in modulating cell cycle progression makes it a valuable tool for investigating mechanisms of cancer therapy and the role of CDK6 in malignancies. -
CDK7 Inhibitor
JNJ-3738 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with a Ki value of 21.75 nM. This compound demonstrates potent inhibitory activity in CDK7 wild-type expressing A549 cells, exhibiting a pIC50 of 7.37. JNJ-3738 is primarily utilized in research applications focused on cell cycle regulation, transcriptional control, and cancer biology. -
CDK12 Inhibitor
PPA-037 is a potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12) with oral bioavailability. By inducing the degradation of cyclin K, PPA-037 enhances antiproliferative effects on various tumor cells. This compound holds significant potential for cancer research applications focused on targeting CDK12-related pathways. -
CDK4-Cyclin D1 Kinase Inhibitor
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a tumor suppressor protein that targets CDK4-Cyclin D1 kinase. This peptide effectively binds to CDK4 and CDK6, demonstrating an inhibitory effect on CDK4-cyclin D1 activity with an IC50 of 1.5 μM. Its mechanism of action leads to the blockade of cell cycle progression through the G1 phase, making it a valuable reagent for cancer research and studies focusing on cell cycle regulation. -
SCDKI Pathway Inhibitor
SNX7 is a selective inhibitor of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. This compound plays a crucial role in studying cellular senescence and various CDKI-related diseases. By targeting the CDKI pathway, SNX7 serves as a valuable tool in cancer research and other conditions where cell cycle regulation is disrupted. -
CDK12/13 Inhibitor
CDK12/13-IN-3 is a selective inhibitor of cyclin-dependent kinases 12 and 13, demonstrating IC50 values of 107.4 nM and 79.4 nM, respectively. This compound effectively inhibits the phosphorylation of Ser2 on the C-terminal domain of RNA polymerase II, leading to DNA damage and downregulation of DNA damage response gene expression. CDK12/13-IN-3 exhibits notable antiproliferative activity against a variety of cancer cell lines and shows significant antitumor effects in mouse models, supported by favorable pharmacokinetic properties, including an oral bioavailability of 53.6%. -
CDK9 Inhibitor
XPW1 is a potent and selective inhibitor of CDK9, a key regulator in transcriptional control linked to cancer progression. This compound exhibits significant anti-tumor activity against clear cell renal cell carcinoma (ccRCC) and demonstrates favorable toxicity profiles. Its unique mechanism of action makes it a valuable tool for research into CDK9's role in cancer biology and therapeutic interventions. -
CDK7 Inhibitor
CDK7-IN-28 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 5 nM. This compound effectively impedes cell proliferation in the MDA-MB-468 cell line by interfering with cell cycle progression and inhibiting DNA replication. Its activity makes it a valuable tool for research into cell cycle regulation and cancer therapeutics. -
CDK2 Inhibitor
CDK2-IN-37 is a selective cyclin-dependent kinase 2 (CDK2) inhibitor that demonstrates significant anti-cancer properties. By effectively inhibiting CDK2 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. This compound is a valuable tool for researchers investigating the role of CDK2 in cancer biology and therapeutic development. -
CDK7 Inhibitor
(E/Z)-THZ1 dihydrochloride is a potent and selective inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 3.2 nM. This compound exhibits significant antiproliferative activity, making it a valuable tool for research in cancer biology and cell cycle regulation. Its ability to inhibit CDK7 can be utilized in studies aimed at understanding transcriptional regulation and therapeutic strategies for various malignancies. -
CDK Inhibitor
(S)-(-)-O-Demethylbuchenavianine is a flavonoidal alkaloid that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1 and CDK5 with IC50 values of 0.03 and 0.05 μM, respectively. This compound is valuable for research applications focused on cell cycle regulation and the investigation of CDK-related signaling pathways. Its inhibitory activity makes it an important tool for studying the role of CDKs in various biological processes and diseases. -
CDK4/6 Inhibitor
Palbociclib dihydrochloride is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) with IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative effects and induces cell cycle arrest in various cancer cell lines. It is particularly relevant for research applications in hormone receptor-positive and HER2-negative breast cancer, as well as hepatocellular carcinoma, providing insights into tumor growth regulation and potential therapeutic strategies. -
CDK4/6 Inhibitor
Palbociclib orotate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), demonstrating IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative activity, effectively inducing cell cycle arrest in cancer cells. Palbociclib orotate is primarily utilized in research focused on HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma, making it a valuable tool for understanding therapeutic strategies in these malignancies. -
CDK1 Inhibitor
CDK1-IN-5 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), demonstrating IC50 values of 42.19 nM for CDK1, 188.71 nM for CDK2, and 354.15 nM for CDK5. By targeting CDK1, this compound effectively disrupts cell cycle progression and inhibits the growth of cancer cells. CDK1-IN-5 is valuable for research applications focused on cancer biology and therapeutic strategies against tumor proliferation. -
CDK4 Inhibitor
Cimpuciclib is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 value of 0.49 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research. Its inhibition of CDK4 disrupts cell cycle progression, thus providing insights into therapeutic strategies for tumors driven by CDK4 dysregulation. -
CDK1 Inhibitor
CDK1-IN-3 is a selective inhibitor of Cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 36.8 nM, 305.17 nM, and 369.37 nM for CDK1, CDK2, and CDK5, respectively. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-3 is valuable for research applications targeting cancer biology and therapeutic development in oncology. -
CDK4/2 Inhibitor
GDC-4198 is an orally active inhibitor of cyclin-dependent kinases 4 and 2 (CDK4/2), exhibiting selective activity against kinases such as CDK6, CDK9, and GSK3β. By inhibiting cyclin-CDK complexes, GDC-4198 effectively blocks the phosphorylation of retinoblastoma protein (pRb), thus halting the cell cycle progression from the G1 to S phase. This compound is a valuable tool for investigating various cancers, particularly breast cancer (especially hormone receptor-positive, HER2-negative), lung cancer, and colorectal cancer. -
CDK Inhibitor
CDK7-IN-2 hydrochloride hydrate is a selective inhibitor of cyclin-dependent kinase 7 (CDK7). This compound demonstrates significant anti-cancer activity by inhibiting CDK7, which is crucial for cell cycle regulation and transcriptional control. CDK7-IN-2 is primarily used in cancer research to explore its therapeutic potential in various malignancies and to investigate CDK-driven signaling pathways. -
CDK7 Inhibitor
BS-181 dihydrochloride is a highly selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of 21 nM, showcasing superior potency compared to alternative compounds. It also exhibits moderate inhibition against CDK2, CDK5, and CDK9, with IC50 values of 880 nM, 3000 nM, and 4200 nM, respectively. BS-181 dihydrochloride has demonstrated the ability to inhibit the growth of various cancer cell lines (IC50 range of 11.5 μM to 37.3 μM) and to induce apoptosis. This compound is valuable for research applications focused on cancer therapies targeting CDK pathways. -
CDK4/CDK6 Inhibitor
CDK4/6-IN-3 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), demonstrating Ki values of less than 0.3 nM and 2.2 nM, respectively. This compound also exhibits inhibitory activity against CDK1 with a Ki of 110 nM. Its ability to penetrate the blood-brain barrier makes CDK4/6-IN-3 a valuable candidate for research into glioblastoma therapies and other malignancies driven by dysregulated cell cycle progression. -
CDK9 Inhibitor
CDK9-IN-9 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 of 1.8 nM. This compound also demonstrates some activity against CDK2, with an IC50 of 155 nM. CDK9-IN-9 has been shown to possess anti-cancer properties, making it a valuable tool for research applications focused on cancer biology and therapeutic development targeting transcriptional regulation mechanisms. -
CDK7 Inhibitor
CDK7-IN-11 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating a high inhibitory activity with an IC50 value of 4.2 nM. This compound is suitable for in-depth research into diseases linked to CDK7 activity, providing valuable insights into its role in cell cycle regulation and transcriptional control. CDK7-IN-11 can aid in the exploration of therapeutic strategies targeting CDK7 in various malignancies and other pathological conditions. -
CDK9 Inhibitor
CDK9-IN-29 is a highly selective inhibitor of Cyclin-dependent kinase 9 (CDK9) with an IC50 value of 3.20 nM. This compound effectively hinders cell proliferation and promotes apoptosis in various cellular models. CDK9-IN-29 is suitable for research focused on cancer biology, particularly studies investigating transcriptional regulation and cell cycle dynamics. -
CDK Inhibitor
Tanuxiciclib trihydrochloride is a potent inhibitor of cyclin-dependent kinases (CDKs), which play a crucial role in cell cycle regulation. By selectively targeting CDK activity, this compound exhibits significant potential in impeding tumor cell proliferation. It is particularly valuable for research applications in cancer biology and therapeutic development, aiding in the exploration of CDK-related pathways and their implications in oncogenesis.
